Amy Bachrodt is currently VP Finance at Maze Therapeutics. Maze was founded by Third Rock and ARCH Ventures with the mission of translating genetic insights into new precision medicines. Amy has over 20 years of experience in Finance working across both multi-billion revenue companies and start-ups. Prior to Maze, Amy joined Myovant Sciences immediately following their IPO and was responsible for building and scaling the FP&A team.
Prior to Myovant, Amy spent 10 years at Genentech with broad exposure across the business, including roles of increasing leadership in Manufacturing, Product Development and eventually leading gross to net across Genentech’s Commercial portfolio. Amy began her career at Ernst & Young and spent her early career focused on fraud & forensic accounting working across a variety of industries. Amy has a MSA in Accounting from University of Notre Dame and a BA in Economics from Denison University in Ohio.